STAT+: New federal rule will require prescription drug middlemen to share secret payments data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration finalized a regulation Thursday requiring pharmacy benefit managers to disclose all fees and compensation received from drugmakers, consulting firms and other entities to the employers that hire them.
- Pharmacy benefit managers must begin the required disclosures on July 1, 2027.
- Disclosure requirements cover drug rebates, spread pricing, and financial relationships with brokers and consultants that could create conflicts of interest.
- Federal officials estimate the rule will apply to more than 70 PBMs and 130,000 employers, saving more than $800 million annually through lower drug costs.
Why it matters: For the 130,000 employers hiring PBMs, required disclosures from July 1, 2027 expose previously protected compensation data, including rebates, spread pricing and financial relationships with brokers and consultants. Federal officials’ estimate of more than $800 million in annual savings adds a direct financial stake to the new transparency requirements.
Ask SkimNews
